$GEF

Greif, Inc. Q3 2026 Earnings Call Summary

Strategic Execution and Operational Resilience Management attributed the 25% adjusted EBITDA growth and 260 basis point margin expansion to structural improvements rather than cyclical market recovery, which remains uneven. The company achieved its $90 million run rate cost optimization milestone ahead of schedule by simplifying the organization and optimizing the manufacturing network.

Original reporting
Published Jul 30, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Greif, Inc. Q3 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$GEFBullishMed
01

Why it matters

Traders can update models for EBITDA trajectory, cash conversion expectations, and capital return pace, while stress-testing assumptions around Middle East volatility and fiber margin recovery into Q4.

02

Market read

Fresh guidance range plus a new buyback authorization are the primary tradable catalysts, with segment margin and geopolitical assumptions shaping near-term risk.

03

What to watch

The guidance assumes offsetting only part of the $20 million geopolitical headwind; any worsening disruption could force further pricing or inventory drawdowns, pressuring cash conversion.

Relevance 7/10Novelty 7/10Timing: after-hours earnings call summary published July 30, 2026

Background

The piece summarizes Greif, Inc. Q3 2026 earnings call themes: cost optimization, segment performance, geopolitical disruption management, updated EBITDA guidance, and capital allocation.

Company-level read

Ticker impact

$GEFBullishMedium confidence
Context

Greif updated EBITDA guidance to $615 million to $635 million and authorized a $150 million stock repurchase plan after Q3 results.

Expected impact

Likely supportive for the stock on open, with upside bias if investors view the Middle East headwind as manageable and cost actions as credible.

Evidence & confidence

The article discloses fresh, decision-relevant items: updated EBITDA guidance, a new $150 million repurchase authorization, and quantified assumptions around a $20 million geopolitical headwind.

Market effects

Polymer and packaging materials demand and pricing dynamics are framed as resilient via daily price/cost adjustments, which may influence sentiment across industrial packaging peers.

Middle East conflict is cited as a direct operational and pricing volatility driver, with inventory and pricing actions used to mitigate regional disruption.

EMEA expansion via Envaplast tuck-in acquisition highlights continued consolidation and market penetration in agrochemical-related polymers.

Counterpoint

RISI non-recognition of price increases and fiber margin pressure from cost inflation could mean reported margin gains are less durable than they appear.

Key entities

  • Greif, Inc.

    Reported Q3 2026 performance, updated EBITDA guidance, authorized a $150 million repurchase, and discussed tuck-in M&A and geopolitical mitigation.

  • Envaplast

    Spain acquisition referenced as providing an EMEA agrochemical market foothold with >18% EBITDA margins.

Related articles

$GEFMed

GREIF, INC (GEF): Results of Operations and Financial Condition

GREIF, INC (GEF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Greif Reports Fiscal Third Quarter 2026 Results DELAWARE, Ohio (July 28, 2026) – Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced fiscal third quarter 2026 results. On June 30, 2025, we entered into a defi

$005930.KSMedAI 8/10

Samsung, SK hynix Set to Post Record Q3 Operating Profit

Samsung Electronics and SK hynix are expected to post record Q3 operating profits, driven by high memory demand and supply shortages. Samsung's profit is estimated at 111.38 trillion won, up 815.47% YoY, while SK hynix's profit is forecast at 78.13 trillion won, up 586.34% YoY. Both companies are focusing on HBM for AI semiconductors, exacerbating general-purpose DRAM shortages.

$SNXMed

TD Synnex: Morgan Stanley lifts price target after strong quarter

Morgan Stanley raised its price target for TD Synnex Corp (NYSE:SNX) to $359 from $334, citing stronger-than-expected earnings, accelerating growth, and improving operating leverage. The company's fiscal third-quarter revenue and EPS beat estimates by 13%-21%, with fourth-quarter guidance 12%-25% above expectations. Analysts also increased fiscal 2027 and 2028 earnings estimates by 12%-15%, driven by enterprise AI demand and new hyperscaler programs.

$LLYMed

Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?

Eli Lilly (LLY) reports that Foundayo, its oral GLP-1 drug, now accounts for about one-third of new patients starting the treatment. Foundayo generated $98 million in Q2 revenue, contributing to Lilly's total Q2 revenue of $23.0 billion, up 48% YoY. Lilly raised its 2026 revenue guidance to $85 billion-$87 billion and is investing $6.5 billion in a new Houston facility to produce Foundayo and other medicines.